Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corp
(NY:
CVM
)
1.720
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.720
Bid (Size)
0.6880 (2)
Ask (Size)
2.150 (1)
Prev. Close
1.720
Today's Range
1.720 - 1.720
52wk Range
1.040 - 3.230
Shares Outstanding
50,104,231
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
April 23, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
Performance
YTD
-36.06%
-36.06%
1 Month
-3.37%
-3.37%
3 Month
-41.10%
-41.10%
6 Month
-26.18%
-26.18%
1 Year
-31.20%
-31.20%
More News
Read More
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Why CEL-SCI Corporation (CVM) Shares Are Diving
February 09, 2024
Via
Benzinga
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
December 27, 2023
Via
InvestorPlace
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 28, 2023
Via
Benzinga
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 04, 2023
Via
Benzinga
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
December 04, 2023
Via
Benzinga
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
Via
FinancialNewsMedia
Exposures
Product Safety
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
October 24, 2023
From
CEL-SCI Corporation
Via
Business Wire
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
October 23, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
October 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
